Table 2 Probability of superiority to placebo in the change from baseline after 2 weeks of treatment and 2 weeks of follow-up for the efficacy endpoints.

Bayesian MMRM model: change from baseline = baseline + treatment + visit + baseline * visit + treatment * visit + site + body weight, with unstructured variance-covariance structure for a dog’s measurements at end of treatment and after 2 weeks of follow-up. ITT population. n, number of evaluable canines at week 2; PIS, Pain Interference Score; PSS, Pain Severity Score.

EndpointPlacebo
(n = 43)
LYA
(n = 39)
LYB
(n = 42)
Carprofen
(n = 39)
CBPI PIS
  Week 2, n43394038
    Posterior mean (95%
credible region)
−1.5
(−1.99, −1.01)
−1.8
(−2.35, −1.34)
−1.5
(−2.05, −1.04)
−2.1
(−2.64, −1.61)
    Probability of
superiority to placebo
80%54%93%
  Week 4, n43393938
    Posterior mean
(95% credible region)
−1.2
(−1.63, −0.80)
−0.7
(−1.10, −0.25)
−1.0
(−1.38, −0.53)
−0.8
(−1.19, −0.34)
    Probability of
superiority to placebo
6%23%10%
CBPI PSS
  Week 2, n43394038
    Posterior mean (95%
credible region)
−1.14
(−1.53, −0.75)
−1.66
(−2.06, −1.25)
−1.39
(−1.79, −0.98)
−1.56
(−1.97, −1.16)
    Probability of
superiority to placebo
94%78%90%
  Week 4, n43393938
    Posterior mean (95%
credible region)
−0.65
(−1.00, −0.31)
−0.70
(−1.05, −0.34)
−0.68
(−1.04, −0.32)
−0.25
(−0.61, 0.11)
    Probability of
superiority to placebo
57%54%8%
CBPI overall impression
  Week 2, n43394038
    Posterior mean (95%
credible region)
0.35
(0.14, 0.56)
0.56
(0.34, 0.78)
0.37
(0.15, 0.59)
0.61
(0.39, 0.83)
    Probability of
superiority to placebo
89%56%93%
  Week 4, n43393938
    Posterior mean (95%
credible region)
0.18
(−0.01, 0.37)
−0.04
(−0.24, 0.15)
0.23
(0.03, 0.43)
−0.04
(−0.16, 0.23)
    Probability of
superiority to placebo
8%6%19%
LOAD mobility
  Week 2, n43394038
    Posterior mean (95%
credible region)
−3.55
(−5.36, −1.74)
−6.17
(−8.05, −4.31)
−5.43
(−7.29, −3.58)
−7.52
(−9.42, −5.63)
    Probability of
superiority to placebo
96%89%99%
  Week 4, n43393938
    Posterior mean (95%
credible region)
−1.53
(−2.90, −0.16)
−1.65
(−3.06, −0.24)
−2.77
(−4.18, −1.36)
−1.52
(2.93, −0.10)
    Probability of
superiority to placebo
54%87%50%